Tacilent

The supplied evidence does not contain any reference to a brand, company, product, or platform named Tacilent. The only source provided is a press release about Debiopharm's MultiLINK linker technology for antibody-drug conjugates, which mentions no entity called Tacilent. No official website, Wikipedia entry, ownership record, headquarters, founding information, product line, or market activity could be attributed to this name. Because the identity of the subject cannot be established from the evidence, this entry is intentionally minimal and flagged for review. It should not be treated as a validated brand dossier until reliable sources describing a commercial entity named Tacilent are located.

• 2026.10.14

  Reported2026.10.14

  Apogee Global RMS launches Rogue Risk Platform powered by Tacilent[2]Apogee Global RMS 推出由 Tacilent 驱动的 Rogue Risk 平台finanznachrichten.de

  On October 14, 2026, Apogee Global RMS launched the Rogue Risk Platform, powered by Tacilent, which unifies cyber, physical, and human risk in a single operating apparatus and anchors the firm's Zenith sustained engagement practice.

• 2026.10.14

  Reported2026.10.14

  Apogee Global RMS announces equity investment in Tacilent[2]Apogee Global RMS 推出由 Tacilent 驱动的 Rogue Risk 平台finanznachrichten.de

  On October 14, 2026, alongside the launch of the Rogue Risk Platform, Apogee Global RMS announced an equity investment in Tacilent, the platform's developer, with Apogee stating it put capital behind the platform to be accountable for how it performs.

Read more

1. 1Debiopharm's Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistancefinanznachrichten.de
2. 2Apogee Global RMS 推出由 Tacilent 驱动的 Rogue Risk 平台finanznachrichten.de